Recommendations for the validation of flow cytometric testing during drug development: II assays
Denise M. O’Hara(Pfizer (United States)), Virginia Litwin(Progenics Pharmaceuticals (United States)), Yuanxin Xu(Nanjing University of Chinese Medicine), Zhiyan Liang(East China University of Science and Technology), Dianna Wu(Memorial Sloan Kettering Cancer Center), Manjula Reddy
Cited by 130
Related Papers
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells
|The Journal of Experimental Medicine|2003|274
Single-atom Mo–Co catalyst with low biotoxicity for sustainable degradation of high-ionization-potential organic pollutants
|Proceedings of the National Academy of Sciences|2023|219